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Abstract 
Phthalates are suspected to be endocrine disruptors. Di(2-ethylhexyl) phthalate (DEHP) is 
assumed to have low dermal absorption; however, previous in vitro skin permeation studies have 
shown large permeation differences. Our aims were to determine DEHP permeation parameters 
and assess extent of skin DEHP metabolism among workers highly exposed to these lipophilic, 
low volatile substances. 
 
Surgically removed skin from patients undergoing abdominoplasty was immediately 
dermatomed (800 μm) and mounted on flow-through diffusion cells (1.77 cm2) operating at 
32°C with cell culture media (aqueous solution) as the reservoir liquid. The cells were dosed 
either with neat DEHP or emulsified in aqueous solution (166 μg/ml). Samples were analyzed by 
HPLC-MS/MS. 
 
DEHP permeated human viable skin only as the metabolite MEHP (100%) after 8 hours of 
exposure. Human skin was able to further oxidize MEHP to 5-oxo-MEHP. Neat DEHP applied 
to the skin hardly permeated skin while the aqueous solution readily permeated skin measured in 
both cases as concentration of MEHP in the receptor liquid. 
 
DEHP pass through human skin, detected as MEHP only when emulsified in aqueous solution, 
and to a far lesser degree when applied neat to the skin. Using results from older in vitro skin 
permeation studies with non-viable skin may underestimate skin exposures. Our results are in 
overall agreement with newer phthalate skin permeation studies. 
 
Keywords:  Di(2-ethylhexyl) phthalate, DEHP, 117-81-7, human, skin, percutaneous permeation 
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List of abbreviations: 
 
2cx-MMHP: mono(2-(carboxymethyl)hexyl) phthalate   
5OH-MEHP:  mono-(2-ethyl-5-hydroxyhexyl) phthalate  
5oxo-MEHP: mono-(2-ethyl-5-oxohexyl) phthalate 
5cx-MEPP: mono-(2-ethyl-5-carboxypentyl) phthalate 
BSA: bovine serum albumin 
CV: coefficients of variation    
DAD:  dermally absorbed dose  
DEHP:  diethyl hexyl phthalate   
DiNP:  diisononyl phthalate   
DiDP:  diisodecyl phthalate    
DBP:  di-butyl phthalate   
EFSA: European Food Safety Authority   
EPA: US Environmental Protection Agency   
ESI: electrospray interface  
EU: European Union 
GHS: Globally Harmonized System of Classification and Labelling of Chemicals 
HGP: hairless guinea pig  
HMWP:  High-molecular-weight phthalates   
HPLC: a high-performance liquid chromatograph   
τ  : lag time   
MBP: mono-butyl phthalate   
MEHP: mono-(2-ethylhexyl) phthalate    
J : permeation rate    
Kp: permeation coefficient 
OECD:  Organisation for Economic Co-operation and Development 
SC: stratum corneum    
TDI: Tolerable Daily Intake   
TEWL: trans epidermal water loss   
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1.0 Introduction 
Phthalates are used to impart flexibility to plastics (plasticizers) and for their solvent properties 
in a wide variety of products (Graham, 1973). High-molecular-weight phthalates (HMWP) 
including diethyl hexyl phthalate (DEHP), diisononyl phthalate (DiNP), and diisodecyl phthalate 
(DiDP) are used in plastic tubing, food packaging and processing materials, containers, vinyl 
toys, vinyl floor coverings, and building products (Kueseng et al., 2007;ATSDR, 1990; ECB, 
2008).  
 
Phthalate exposures have produced a variety of male reproductive effects in animal studies 
(classified in the EU as category 2 substances to reproduction and as 1B in the GHS based 
classification system) (Skakkebaek et al., 2001). Phthalates may be absorbed into the body after 
ingestion, inhalation, and dermal exposures. The proportional contribution from each route of 
exposures is not known. Highly lipophilic substances such as phthalates are assumed to have low 
dermal absorption; however, few dermal absorption studies have included the skin’s possibility 
to metabolize phthalates. Skin permeation rates used in dermal exposure assessments might 
therefore underestimate the absorbed dose in health risk assessments.  
 
Human phthalate exposure is usually assessed by measuring urinary metabolites as the 
proportional contribution from the various sources and routes of exposure to phthalates is 
unknown. Phthalates are rapidly metabolized and excreted in urine and faeces after oral 
administration (ATSDR, 1990). An initial de-estrification of one alkyl linkage to the 
corresponding monoesters (one carboxylic acid and one ester substituent) is followed by an 
enzymatic oxidation of the alkyl chain, to more hydrophilic, oxidative metabolites  after oral 
administration (Hauser and Calafat, 2005). For diethylhexyl phthalate (DEHP), the resulting 
monoester, mono-(2-ethylhexyl) phthalate (MEHP) is further oxidized, mainly by ω-oxidation at 
the terminal carbon of the alkyl ester side chain, to: mono-(2-ethyl-5-hydroxyhexyl) phthalate 
(5OH-MEHP), mono-(2-ethyl-5-oxohexyl) phthalate (5oxo-MEHP), mono-(2-ethyl-5-
carboxypentyl) phthalate (5cx-MEPP), and mono[2-(carboxymethyl)hexyl] phthalate (2cx-
MMHP) . The 5cx-MEPP is the primary metabolite (greater than 25%) in humans (Wittassek and 
Angerer, 2008), and MEHP is detected in typically less than 10% of the absorbed dose in the 
general population (Barr et al., 2003; Koch et al., 2003). After 24 hours post oral administration 
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to human volunteers, the urinary excretion for the sum of these five metabolites was between 65 
and 70%, and half lives were between 2 and 24 hours (Koch and Angerer, 2007; Koch et al., 
2005).  
 
Workers manufacturing products containing phthalates are highly exposed and have shown to 
have urinary metabolite concentrations that often exceed those at the 95th percentile of the 
general population (NRC 2008). HMWPs are not very volatile, but they readily form aerosols 
that may be inhaled especially during work with heated processes (Smith et al., 1980). Dermal 
exposures could potentially play a role in non-heated processes; however, due to their 
lipophilicity dermal phthalate absorption is assumed to be low or negligible. This assumption 
might be false as several studies among HMWP exposed workers performing non-heated 
processes (Gaudin et al., 2011; Gaudin et al., 2008; Hines et al., 2008; Hines et al., 2009; Koch et 
al., 2012) have demonstrated the presence of urinary HMWP metabolites.  
 
Gaudin et al. (Gaudin et al., 2011; Gaudin et al., 2008) found elevated urinary 5cx-MEPP 
metabolite concentrations (median 107.5 μg/L) among workers preparing DEHP-containing 
plastisol at room temperature and supervising the plastisol coating of glass flasks automatically 
dipped into vats filled with the plastisol. Moreover, Hines et al. (Hines et al., 2008) found 
elevated urinary 5OH-MEHP and 5oxo-MEHP (44.0 and 34.3 μl/L, respectively) among workers 
manufacturing vehicle filters with DEHP-based plastisol. In a very recent study (Koch et al., 
2012); plastisol workers refinishing phthalate-containing sealants at room temperatures had 20 
times higher DiNP/DiDP metabolite concentrations than the control group. Koch et al. (Koch et 
al., 2012) also found pre-shift urine samples to contain elevated phthalate metabolite 
concentrations, and the metabolite distribution was significantly different from oral studies. Two 
possible explanations were proposed by the authors: “(1) the maximum elimination was not 
achieved directly after the shift; or (2) skin metabolism might produce slightly different 
metabolite distribution than after oral exposure.”. Differences in metabolism may have potential 
implications for risk estimates. Therefore, improved knowledge concerning the dermal 
metabolism may provide better risk estimates of phthalate toxicity. 
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Human skin permeation may be efficiently evaluated using in vitro flow-through diffusion cells 
with fresh (metabolically active) excised skin. In this system the skin is isolated with no 
metabolic interference from enzymes in other parts of the body (Bronaugh, 2005). Flow-through 
diffusion (Bronaugh et al., 1982) cells are characterized by a continuously replaced receptor 
fluid, which represents to some extent in vivo conditions. This system is in particular suitable for 
phthalates which have very low solubility in the water based receptor fluid, increasing the sink 
conditions by continually replacing the receptor fluid (Brain et al., 1998). The primary barrier to 
skin absorption is often the nonliving stratum corneum (SC) layer on the surface of the skin, and 
metabolism occurs after SC permeation. For compounds that are insoluble in water and very 
soluble in oil such as for DEHP, the primary barrier to permeation shifts from the SC to the 
aqueous viable epidermis (Elsisi et al., 1989). The activity of skin soluble enzymes such as 
esterases, acetyltransferease, and alcohol and aldehydes dehydrogenases have been shown to 
substantially metabolize substances applied to viable skin in diffusion cells (Bronaugh, 2005). 
OECD (Guideline 427) recommends using human viable skin, although few skin permeation 
studies do, probably due to limited access.  
 
Previous in vitro studies have shown large differences for DEHP permeation (Table 1), which 
could partially be explained by the difference in methods, especially the use of animal or non-
viable skin. Our study is a first attempt to measure the DEHP permeation rate through excised 
human viable skin in the flow-through diffusion cell system. Specifically, our aims were: 1) 
Determine DEHP lag time (τ), permeation rate (J) and permeation coefficient (Kp); 2) Assess 
extent of DEHP skin metabolism; and 3) Estimate skin absorption in a simple occupational 
exposure task using the obtained permeation parameters.  
 
2.0 Materials and Methods 
2.1 Chemicals and materials 
DEHP (CAS no. 117-81-7, molecular weight 390.6 g/mol, water solubility 41 μg/L at 25C 
(Leyder and Boulanger 1983), pKow 4.2-5.11, density 0.984 g/mL, vapour pressure 6.2 × 10-8 
mm Hg at 25 °C) (99.5% pure) was obtained from Sigma-Aldrich (Buchs, Switzerland), while 
deuterated DEHP (d4-DEHP) was obtained from Cambridge Isotope Laboratories (ReseaChem 
GmbH, Burgdorf, Switzerland). MEHP (99.5% pure) was obtained from AccuStandard Europe 
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(Niederbipp, Switzerland). The cell culture media, RPMI-1640 Medium HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) Modification (R5886) was purchased from 
Sigma-Aldrich (Buchs, Switzerland). 
 
2.2 Human skin 
Surgically removed skin from patients undergoing abdominoplasty at the Department of Plastic 
and Reconstructive Surgery at the Cantonal University Hospital (Centre Hospitalier Universitaire 
Vaudois) in Lausanne, Switzerland, was collected immediately after removal. This skin still 
attached to its subcutaneous fatty layer, was brought to our laboratory in an ice-box and 
dermatomed. No more than 2 hours elapsed from time of surgery-end to the skin was placed in 
the flow-through diffusion cells. The surgeon obtained patient consent for the use of the removed 
skin in our experiments after human ethics approval. No personal information regarding the 
patients (gender, age, ethnicity, BMI, etc) was retained.  
 
2.3 Flow-through diffusion cell experiments 
A rack of six jacketed flow-through diffusion cells (receptor volume 8.5mL; 11.28 mm diameter 
opening; PermaGear bought from SES Analytical System, Bechenheim, Germany) was operated 
at 32°C. A fraction collector (FC 204, Gilson Inc., Middleton, WI, USA) automatically sampled 
the reservoir liquid. The peristaltic pump (Ismatec IPC-N, IDEX Health & Science GmbH, 
Wertheim-Mondfeld, Germany) was set at 40 µl/min, and replaced the collected reservoir liquid. 
The exposed skin area was 1.77 cm2. Before each experiment, the system was rinsed with 
ethanol overnight followed by 2-3 hours of rinse with the receptor fluid prior to experiment to 
evacuate ethanol from the system. The skin was dermatomed (Acculan®II, B. Braun/Aesculap, 
Sempach, Switzerland) to a thickness of 800 µm. The six skin discs were mounted onto the 
diffusion cells filled with buffer solution (cell culture media), and the pump was calibrated after 
the skin had stabilized (approximately 30 min) determined by stable trans epidermal water loss 
(TEWL) (VapoMeter wireless, Delfin Technologies Ltd., Kuopio, Finland) readings. If the 
TEWL reading was above 11 g/m2/h (Pinnagoda et al., 1990), the skin disc was deemed damaged 
and replaced. The cells were dosed either with neat DEHP (2 ml) representing exposures among 
workers manufacturing DEHP or emulsified in buffer solution (d4-DEHP [166 μg/ml], MEHP 
[166 μg/ml]; 1.5 ml) representing aerosol exposures (the system does not allow the generation of 
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aerosols depositing directly on the skin disks). DEHP applied doses per cm2 of skin were 
calculated to be 1,114.1 mg/cm2 for neat and 140.7 mg/cm2 for emulsified DEHP, respectively. 
The automated sampling collection was set for intervals lasting either 24 or 72 hours. Samples 
were collected in DEHP free vials.  
 
2.4 Chemical analysis 
The collection vials from the flow-through diffusion cell experiments were frozen at -20°C and 
shipped to the laboratory (the Institut National de Recherche Scientifique (INRS), France) for 
analysis under dry-ice and arrived frozen. Analyses of DEHP and its metabolites have been 
described previously, and only slightly modified (Gaudin et al., 2008). Briefly, samples were 
injected into a high-performance liquid chromatograph (HPLC) with an on-line extraction on a 
restricted access material (Lichrospher RP-8 ADS from Merck-Darmstadt, Germany), followed 
by an analytical separation on a column (Phenomenex-Synergi 4 lm Polar-RP column; 80 Ǻ, 
150x25 mm).The analytes were then detected and quantified by MS/MS (1200 L Varian®) after 
introduction into an electrospray interface (ESI) in negative mode. The coefficients of variation 
(CVs) of the precision (intra- and inter-days) were <5%% for the three metabolites at any level 
(5, 10, 20, 100, 200 g/l). The quantification limits were 0.5 for MEHP, 5OH-MEHP, and 5-oxo-
MEHP.  
 
2.5 Data analysis 
Permeability coefficients (Kp) were estimated from the slopes of the cumulative absorption plots 
over time. Lag times (τ) were estimated as the intercept of the steady state portion of the 
permeability rate (J) curves with the time axis. Individual Js were calculated from each diffusion 
cell and the average and standard deviations were calculated for the group. The Kp were 
estimated by dividing J with the density of chemical (DEHP as it was used neat) or concentration 
(d4-DEHP and MEHP). Our study complies with the OECD guideline 428 in describing the skin 
origin and preparation and the proof of skin integrity using the TEWL, temperature (32°C), the 
choice of a suitable receptor fluid, the description of the diffusion cells used, the actual area of 
skin dosed, the number of cells/samples and donors (n=4), the duration of sampling period (24h), 
but does not include the determination of the amount retained in skin after washing. 
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3.0 Calculation of dermally absorbed dose 
Skin absorption dose in a reasonable but hypothetical occupational exposure task: Due to 
maintenance reasons the vat containing the DEHP must be opened once per day, 200 times per 
year, and both hands will be immersed (800 cm2) for about 3 minutes in the solution: (a) DEHP 
in aqueous solution with a concentration of 166 μl/ml (b) neat DEHP. The obtained permeation 
coefficient (Kp) was used in to calculate dermally absorbed dose (DAD) in mg/kg/day (EPA 
1992). 
𝐷𝐷𝐷𝐷𝐷𝐷 = 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 ∗ 𝐸𝐸𝐸𝐸 ∗ 𝐸𝐸𝐷𝐷 ∗ 𝐸𝐸𝐸𝐸 ∗ 𝐷𝐷
𝐵𝐵𝐵𝐵 ∗ 𝐷𝐷𝐴𝐴
 
Where: 
DAevent  absorbed dose per event (mg/cm/event) = 𝐾𝐾𝐾𝐾 ∗ 𝐶𝐶 ∗ 𝐷𝐷  
where  
Kp (cm/h) is the coefficient of percutaneous permeation obtained in our study 
and by Ng et al., 1992,  
C is the concentration of DEHP applied to the skin (mg/L) 
t is the duration of exposure (h) 
 
 
 
0.27*10-5 
1.66 
0.16 
EV event frequency (events/day) 1 
ED exposure duration (years) 1 
EF exposure frequency (days/year) 200 
A skin surface area (cm2) 800 
BW body weight (kg) 70 
AT average time in days for non-carcinogens AT = ED 1 
 
 
4.0 Results 
When d4-DEHP emulsified in cell culture media (RPMI) (aq) was applied to the skin, no d4-
DEHP nor non-deuterated DEHP (aq) were detected in the reservoir fluid (n=6). All the DEHP 
had metabolized and only mono-ester metabolite (d4-MEHP) was detected. The mass 
accumulation curves for d4-MEHP after dosing with neat d4-DEHP and for DEHP (aq) are shown 
in Figs. 1 and 2, respectively. The τ, Kp, and J for d4-DEHP are given in Table 2. Since no d4-
DEHP was detected in the reservoir fluid, we continued our experiments by applying DEHP (not 
deuterated) in the following experiments (n=18) as the results from the previous experiments 
showed no confounding from background DEHP contamination, and the non-deuterated 
chemical was a cheaper alternative. MEHP was not metabolized further in these experiments (no 
5-oxo-MEHP or other metabolites were detected in the reservoir fluid). Overall, the lag-time 
quadrupled, the permeation coefficient reduced more than a hundred times, and the permeation 
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rate dropped 19-fold for neat compared to aqueous DEHP. The skin permeation resulting from 
applying neat DEHP was extremely low, while applying aqueous DEHP was considerable. 
 
When MEHP emulsified in buffer (aq) was applied to the skin the lag-time was reduced 6-fold 
compared to applying neat DEHP and by 2h compared to emulsified DEHP (aq) (Table 2). Kp 
and J were increased considerably for emulsified MEHP compared to DEHP (Table 2). In the 
same experiment, the oxidized MEHP metabolite, 5-oxo-MEHP, was also detected. The mass 
accumulation curves for MEHP and 5-oxo-MEHP are shown in Figs. 3 and 4, respectively. The 
lag-time was the same for MEHP and 5-oxo-MEHP (6 h), while Kp was greatly reduced and J 
was almost 2000 times slower for the secondary metabolite.  
 
The dermally absorbed dose (DAD) estimated for the maintenance task for (a) DEHP in aqueous 
solution was 2.85*10-2 mg/kg/day using our Kp (15.1 * 10-5 cm/h) and 1.02*10-2 mg/kg/day 
using the Kp (0.27 * 10-5 cm/h) obtained by Ng et al., 1992 (Table 1); and (b) DEHP neat was 
1.49*10-4 mg/kg/day (Kp 0.13 * 10-5 cm/h) (Table 2).  
 
5.0 Discussion 
Only the MEHP metabolite (100%) was detected in the receptor fluid when DEHP diluted in 
aqueous cell culture media (RPMI) was applied to human viable skin. DEHP application as neat 
or in aqueous solutions had an enormous impact on viable human skin permeation; neat DEHP 
hardly permeated skin and only did so after 30 hours, while the aqueous DEHP solution 
permeated skin after 8 hours as MEHP. MEHP diluted in aqueous cell culture media applied 
directly onto human viable skin permeated after only 6 hours. In addition, MEHP was oxidized 
further to 5-oxo-MEHP, although the permeation rate for the 5-oxo-MEHP metabolite was 2000 
times slower than MEHP. The permeation rate (J) was 20 times slower when neat DEHP was 
applied to the skin compared to DEHP diluted in aqueous cell culture media. Our results show 
DEHP permeating human skin, contrary to some older human skin permeation studies which 
concluded that DEHP skin penetration is negligible (Barber et al., 1992). In the older studies, the 
total metabolites were less than 2.5% of applied dose compared to our 100%. This could 
potentially be due to a difference in esterase property between HPG and human skin. However, 
these older studies used non-viable skin, which might explain the differences observed. More 
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recent phthalate skin permeation studies (Beydon et al., 2010) have shown similar results to ours, 
namely that phthalates do permeate human skin but not as the parent compound but rather as 
metabolites.  
In vitro skin permeation (Kp) previously reported for DEHP ranged from 0.011 x 10-5 (Barber et 
al., 1992) to 94 x 10-5 (Pelling et al., 1988)  cm h-1 (Table 1), and ours fall in between (15 x 10-5 
cm h-1 DEHP (aq)). This large variability in Kp might only partially be explained by the use of 
animal or human skin; but also the use of viable and non-viable skin, especially for chemicals 
metabolized in skin as we observed for DEHP. These earlier studies used heat separated skin, 
which after being immersed in 60ºC water would have lost considerably their enzyme activity, 
resulting in skin permeation due to diffusion only and not resembling what actually happens in 
human skin. In a study (Ng et al., 1992) comparing viable to non-viable dermatomed hairless 
guinea pig (HGP) skin, the authors found the viable skin to be metabolically active, producing 
twice the amount of metabolites compared to non-viable HGP skin.  
 
Several factors govern the DEHP permeation rate through skin (permeability determinants), 
among those observed in our study were: DEHP solution applied (neat and aqueous solution), 
human skin (quality), and viability (assessed with TEWL), which determines the extent of 
metabolism. Other permeability determinants exist but were not explored in this study such as 
the choice of reservoir fluid, skin type (animal versus human, gender, age, type), storage (fresh 
and frozen), skin thickness, and SC separation methods (heat, NaBr, dermatomed). The vast 
number of permeability determinants complicates comparisons with other studies. Another large 
source of variability is between human skin samples, which might be underestimated in our 
study as only four donors were used for the experiments.  
 
DEHP permeation rates are significantly influenced by the choice of receptor fluid. Receptor 
fluids should not restrict the permeation of the applied chemical (Howes et al., 1996); however, 
with very lipophilic substances such as DEHP the choice of receptor fluid is not clear.  To 
overcome solubility restrictions, bovine serum albumin (BSA) is recommended added to the 
receptor fluid (OECD 2003); however, this addition should be questioned as 5% BSA have 
shown to inhibit skin metabolism, and therefore interfere with permeation (Haberland et al., 
2006; Zhang et al., 2009). Using ethanol in the receptor fluid as in earlier experiments (Pelling et 
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al., 1998) will not allow for metabolism as the skin will not remain viable.  Cell culture buffers 
(RPMI 1640 solution) may be good alternatives as they allow for skin metabolism, which has 
been shown in a recent study with di-butyl phthalate (DBP) (Beydon et al., 2010). For these 
reasons, we chose RPMI 1640 without BSA, which may explain the extensive DEHP 
metabolism observed in our experiments. Increased agreement between studies could be 
achieved if variability decreases, especially through promulgation of standardized guidelines for 
in vitro skin absorption studies (Ng et al., 1992) including how to handle possible dermal 
metabolism and to facilitate partitioning of metabolites into the receptor fluid, which may affect 
the biological activities of dermally applied compounds (Ng et al., 1992). Other variabilities are 
not inherent to the methods but rather due to human factors such as esterase activity necessary to 
hydrolyze DEHP to its metabolite MEHP, which differ between humans and genders (Zhang et 
al., 2009). Intra individual coefficient of variance was 21-109% for the mono ester metabolite of 
DBP in a human volunteer study (Janjua et al., 2008), and individual day to day variations were 
17-78%. 
 
 
Cutaneous esterases are located in the epidermis and in skin associated glands such as hair 
follicles (Muller et al., 2003), not in SC. Hair follicles are also in charge of skin homeostasis. 
Skin is capable of a variety of biotransformation processes including enzymatic process 
(however, much less compared to liver oxidation) (Bronaugh et al., 1994). Hydrolysis has also 
been observed in non viable skin (Bronaugh et al., 1994). Esterase activity might also differ 
between genders (Boehnlein et al., 1994). The importance of metabolism during percutaneous 
absorption depends on structure and biological activity of the penetrating compound and 
metabolite. For example in a very recent in vitro dermal study of [14C]DBP applied to previously 
frozen human skin only MBP was found in the receptor fluid (Beydon et al., 2010). This was 
similar to our study where only MEHP was found in the receptor fluid after DEHP was applied 
to fresh human skin, suggesting that the esterase activity does not diminish after freezing. 
Beydon et al. (Beydon et al., 2010) also showed that inhibition of skin carboxylesterases 
decreased DBP skin permeation considerably, indicating that DBP itself cannot pass through 
skin without skin esterase hydrolysis. This might not be completely true as other studies (Scott et 
al., 1987) have shown that DBP and DEHP can penetrate the SC. 
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The SC is considered the rate limiting skin permeation step; however, in our study the rate was 
primarily determined by whether DEHP was applied neat or in aqueous solution. A chemical 
interpretation of this would be that DEHP, an extremely lipophilic substance, applied neat will 
reluctantly diffuse into the comparatively less lipophilic SC as seen with the long lag-time (>30 
h), while aqueous DEHP have less affinity to water  and prefer the lipophilic SC as seen with the 
much higher permeation rate. Once DEHP (aq) has permeated SC, it will immediately be 
hydrolyzed as shown with its similar permeation rates to the experiment with MEHP (aq) applied 
to the skin. In both cases, MEHP was measured in the reservoir fluid. This suggests that the rate 
limiting step is the availability of DEHP in the dermis (aqueous phase) for the aqueous DEHP 
was the diffusion through the SC rather than the metabolism of DEHP to MEHP by esterases. 
We could not evaluate the relative contribution of the two skin layers; epidermis and dermis, in 
our study because we did not use radio labelled DEHP and MEHP. Other researchers (Pelling et 
al., 1998) have found that in phosphate buffer during the first few hours after the lag phase, 
[14C]DEHP absorption through the dermis (Tlag = 2.5h; Kp = 4.76 x 10-5 cm/h) was 3.7 times 
faster than through the epidermis (Tlag = 0.9h; Kp = 1.3 x 10-5 cm/h). In light of new research, we 
know that DEHP does not diffuse through the dermis but rather DEHP diffuses through SC and 
undergo metabolism in the dermis. It is currently very difficult to know which strata is the 
limiting factor. In a recent study (Beydon et al., 2010), permeation rates for MBP were 8–120 
times faster than  DBP for the same dose deposited, suggesting the DBP metabolism to be the 
rate limiting step of the percutaneous DBP absorption. Absent from their discussion was the 
application of DBP as neat and MBP as diluted in acetone, which can influence phthalate 
diffusion through SC as seen in our study and in an earlier study (Frasch et al., 2007) of the more 
volatile phthalate, diethyl phthalate (DEP). DEP skin permeation rates were almost double for 
DEP applied as a saturated aqueous solution compared to neat. From pharmaceutical research, it 
is known that the choice of vehicles can inadvertently cause changes in dermal absorption 
(Zhang et al., 2009). For example, alcohols (e.g. ethanol) used as solvents in topical dosing can 
interact metabolically by a transesterification reaction with the substrate of interest (e.g. inhibited 
the enzymatic conversion of beta-estradiol to estrone) (Oesch et al., 2007); and fatty ointments 
can impair enzymatic ester cleavage within the skin and reduce metabolism (Zhang et al., 2009). 
Moreover, chemical enhancers commonly used to increase drug delivery are alkyl esters. These 
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“prodrugs” increase skin permeation by being rapidly hydrolyzed in the epidermis creating “sink 
conditions” as observed when synthesized alkyl esters of morphine (more lipophilic than 
morphine) enhanced the delivery of morphine 2 to 5 times in aqueous solution while decreased 
delivery in oil (Zhang et al., 2009). Phthalates have two alkyl ester groups, making them 
excellent “prodrugs”, as observed in our study where the two-alkyl ester DEHP increased the 
permeation of the mono-alkyl ester MEHP. 
 
The total dermal dose DAD estimated for a work scenario changed drastically between the neat 
and aqueous DEHP (0.15 vs. 28.5 µg/kg bw/day, respectively) due to the differences in Kp. We 
compared our results to the study of Ng et al., (1992) because they also used dermatomed viable 
skin and a buffer as the receptor fluid as opposed to the two studies using human skin (Scott et 
al., 1987 used non-viable skin and 50% aqueous ethanol as the receptor fluid or Barber et al., 
1992 who used non-viable heat separated human skin). The DAD calculated with our Kp was 
almost three times greater compared with the dose (10.2 µg/kg bw/day) calculated with an 
already published DEHP Kp (Ng et al., 1992).  Both were above the daily intake calculated for 
the general population in Germany (Wittassek et al., 2007) (50th percentile geometric mean 3.5 
µg/kg bw/day), and US Environmental Protection Agency (EPA) reference dose (oral, 20 µg/kg 
bw/day), but below the European Food Safety Authority (EFSA) Tolerable Daily Intake (TDI) 
(50 µg/kg bw/day). Our values were similar to estimated daily intake (Hines et al., 2011) for 
workers manufacturing or using DEHP (Hines et al., 2008), suggesting that dermal uptake is not 
negligible for these workers.   
 
Lipophilic chemicals will remain in the SC for some time before being absorbed into the general 
circulation. This phenomenon has in particular two regulatory implications when calculating the 
total absorbed dose (%). In an in vitro experiment, [14C]DBP (7%, typical cosmetic exposure) 
was applied to skin and 27% of administrative dose was found in the receptor fluid while ~30% 
in the skin, of which 14% in the SC (Doan et al., 2010). Calculation of “total dose absorbed” 
depends on the intentions of DBP use; for an “industry setting” where OECD guidelines apply, 
DBP in the SC must be included (giving a total of 57% DBP absorption); while for “non-food” 
where European Union’s Scientific Committee on Cosmetic Products and Non-Food Products 
Intended for consumers (SCCP, 2007) apply, DBP in SC must be excluded (giving a total of 43% 
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DBP absorption). (DEHP is not permitted for use in cosmetics in the European Union 
(Commission Directive 2004/93/EC)). 
 
Under the EU Regulation (EC No 1907/2006) concerning the Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH) exposure assessments including the 
dermal route have to be calculated. The validity of the exposure assessment depend on existing 
dermal absoption studies. In general, these studies are few and inconsistent (also true for 
phthalates, see Table 1), and often based on animal data, which cannot be readily applied for 
humans as human skin is less permeable (IOM, 2004). This is not the case for DEHP where the 
Kp obtained using viable dermatomed Guinnea pigs were 56-fold lower than what we obtained 
in this study using viable dermatomed human skin, leading to an underestimate of the dermally 
absorbed dose for aqueous DEHP. The difference is in the extensive metabolism observed in 
human fresh skin.  
 
Although a regulatory binding biological monitoring limit value has not been set for phthalates 
as of yet, the use of the urinary phthalate metabolites have been used extensively to assess total 
phthalate exposures. The validity of biological monitoring must be questioned as the timing of 
the sample which relates to the time between exposure and time for blood or urine sampling 
determines the collection time. Failure to consider the lag time between dermal exposure and 
appearance of phthalate or metabolites in the general circulation may cause false conclusions 
about exposure (Nielsen and Nielsen, 2000). The optimal collection time in our hypothetical 
maintenance scenario would be after dermal permeation (Tlag of 8h) and clearance from blood 
(estimated by the parenteral route (Pollack et al., 1985; Sjoberg et al., 1985) (half-life of 10 h), 
meaning urinary collections should start 18 h after the task started. Several occupational 
exposure studies (Gaudin et al., 2011; Gaudin et al., 2008; Koch et al., 2012) have found pre-
shift urine samples to contain elevated phthalate metabolite concentrations, which support the 
hypothesis postulated by Koch et al., (Koch et al., 2012): “the maximum elimination was not 
achieved directly after the shift”, and this would be due to the dermal exposures associated with 
longer clearance times. 
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Exposure to DEHP remains important with respect to human exposures as it can impair fertility 
to humans or cause development toxicity in humans (classified in the EU as category 2 
substances to reproduction). Absorption of DEHP through the dermal route is significant, and not 
as currently regarded: negligible or low. In addition, skin is an endocrine organ containing 
estrogen receptors (ERα and ERβ) (Thornton, 2002). DEHP and MEHP can bind to estrogen 
receptors. Both DEHP and MEHP have shown low antiandrogenicity effect in an in vitro study 
(Christen et al 2010), thus the endocrine activity would not be effectively reduced in the first 
DEHP metabolism step. What endocrine effects this might exert is currently unknown and needs 
further scrutiny.  
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